Increasing evidence indicates that chemotherapy efficacy is closely linked to the tumor immune microenvironment, suggesting that immune-related molecular signatures may improve response prediction.<h4>Methods</h4>A total of 2,385 pretreatment HER2-negative breast cancer patients from ten GEO cohorts were included. The gene discussed is ERBB2; the disease is breast carcinoma.